Replies to post #140302 on Biotech Values

[mcbio]

I assume this means that the trial enrollment size will be increased to include a substantial number of FR+ patients. I initially thought it meant there would be a 2nd trial with just FR++ patients and a small number of FR+ patients based on PFS as the PE but the PR doesn't indicate a 2nd trial is in the offing. A second trial showing significant PFS results would improve the approvability odds since EC145 showed significant PFS results in the FR++ patients in both sets of scans.

I'm not certain, to be honest. And if this was addressed in the CC, I missed it.

Overall it looks like an impressive deal and, based on the terms, a better deal than the one THLD signed with Merck KGaA.

Agreed.

[GrthzGd]

Overall [ECYT] looks like an impressive deal and, based on the terms, a better deal than the one THLD signed with Merck KGaA.

My impression from the transcript, and from the deal itself, is that Endocyte managed to get quite a bidding war going among Big Pharma, resulting in: a nice chunck of cash, solid milestones, a royalty, much of ECYT's technology remaining in the kitty, a marketing partner. What's not to like? Also, the price previously hovered above 11 anyway. Yrs truly sold out yesterday, then cravenly bought back in. So far, no regrets.